 Home > Biochemistry News > Biotechnology News > Phase IIb clinical results of antisense oligonucleotide therapy positively significantly reduce blood lipid levels

Phase IIb clinical results of antisense oligonucleotide therapy positively significantly reduce blood lipid levels

 Last Update: 2022-01-12
 Source: Internet
 Author: User

Tags

venlafaxine 150 mg

calcium 500 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Author: Shi Bei

On November 24, Ionis announced that the vupanorsen (IONIS-ANGPTL3-LRx) jointly developed with Pfizer has achieved positive results in the Phase IIb study

ANGPTL3 protein is a key regulator of triglyceride and cholesterol metabolism

This global multicenter, double-blind, placebo-controlled Phase IIb RANSLATE-TIMI 70 study enrolled 286 dyslipidemia patients (≥40 years old, non-HDL-C (≥100 mg/dL) and TG (150-500 mg) /dL) is elevated and is receiving a stable dose of statins)

The results showed that compared with placebo, at week 24, subjects in all dose groups of vupanorsen achieved a statistically significant reduction in non-HDL-C levels, reaching the primary endpoint

In terms of safety, the most common adverse event was an injection site reaction, which most often occurred in the highest dose group of vupanorsen

Vupanorsen was developed by Ionis through its advanced ligand-conjugated antisense (LICA) technology

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.